SOUTH SAN FRANCISCO, Calif., July 26, 2013 (GLOBE NEWSWIRE) -- diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it will host a conference call and webcast on Thursday, August 8, 2013 at 4:30 PM ET (1:30 PM PT) to discuss its 2013 second quarter results.
The dial-in numbers for the conference call are 1 (877) 378-9048 for domestic callers and 1 (706) 679-2272 for international. The reservation number for both is 22881539. The webcast may be accessed via the company's website at www.diadexus.com/webcast. A replay of the webcast will be available shortly following the live webcast.
About diaDexus, Inc.
diaDexus, Inc., based in South San Francisco, California, develops and commercializes proprietary cardiovascular diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC® Test ELISA Kit is the only blood test cleared by the FDA to aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. The company's PLAC® Test for Lp-PLA2 Activity, a CE-marked test, is an indicator of atherosclerotic cardiovascular disease, the #1 cause of death in Europe. diaDexus is ISO 13485 certified and is manufacturing the PLAC Test for Lp-PLA2 Activity on-site. For more information, please visit the company's website at www.diaDexus.com.
CONTACT: Company Contacts: diaDexus, Inc. Brian E. Ward, Ph.D., CEO Jean-Frederic Viret, Ph.D., CFO 650-246-6400 investors.diadexus.com Investor Relations: The Ruth Group Zack Kubow 646-536-7020 email@example.comSource: diaDexus, Inc.